Eagle Bay Advisors’s Puma Biotechnology PBYI Stock Holding History

Eagle Bay Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,500	Closed	-$18.5K	–	954
2022 Q2	$18.5K	Buy	+6,500	New	+$16.2K	0.01%	568

Other funds holding PBYI

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

Eagle Bay Advisors's PBYI Position: Q3 2022 in Review

Eagle Bay Advisors sold out of Puma Biotechnology (PBYI) in Q3 2022, closing a stake of 6,500 shares — an estimated $18.5K sold.

Eagle Bay Advisors first reported a position in PBYI in Q2 2022 and held it in 1 quarter. The position peaked at $18.5K in Q2 2022. 83 funds tracked by Wall St. Rank hold PBYI as of Q3 2022.

Eagle Bay Advisors reported no remaining Puma Biotechnology position as of Q3 2022 after selling out during the quarter.
Eagle Bay Advisors sold 6,500 Puma Biotechnology shares in Q3 2022, an estimated $18.5K.
Eagle Bay Advisors first reported a position in Puma Biotechnology in Q2 2022 and held it in 1 quarter.
Eagle Bay Advisors's Puma Biotechnology position peaked at $18.5K in Q2 2022.
83 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2022.

Based on Eagle Bay Advisors's 13F filing for Q3 2022, filed 23 Nov 2022.